Source: yahoo_news
Source ID: yahoo:6e3b41c409ae656b73424bfef1a7a2cf:ANAB
URL: https://finance.yahoo.com/m/3d854e16-d8a8-3955-b079-1d3308c86229/why-this-ipo-stock%2C-an.html?.tsrc=rss
Symbol: (ANAB)
Published: 2026-10-12 16:10:16 EDT
Time precision: minute
Title: Why This IPO Stock, An AnaptysBio Spinoff, Just Surged

First Tracks Biotherapeutics posted "impressive" results for its celiac disease treatment Monday, and the IPO stock surged.